Baudax Bio Inc BXRXQ

Healthcare

Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.

GREY:BXRXQ - Post by User

Baudax Bio Inc

Bullboard Posts

Next >>

Post by Subchimes1on Mar 11, 2020 4:15pm

113 Views

Post# 30795317

FDA approval

They got FDA approval, the debt facility is coming, a wonderful replacement to opioids, I hope we can see all this reflected in the stock price soon. Very cheap here in my opinion.

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 8, 2024)